Treatment with PCSK9 inhibitors has been proven effective in reducing the volume of atherosclerosis (Ako et al., 2019), leading to plaque regression and enhanced stability (Nicholls et al., 2016; Sugizaki et al., 2020). The gene discussed is PCSK9; the disease is atherosclerosis.